CRISPR Therapeutics CRSP Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $347.56M+16.5% | $298.26M-23.4% | $389.48M+83.8% | $211.89M-77.0% | ||
| $1.63B+1.4% | $1.61B+23.1% | $1.3B-18.7% | $1.6B+10.1% | ||
| $7.63M-33.8% | $11.52M-0.6% | $11.59M-0.4% | $11.64M-31.2% | ||
| $0-100% | $25M-87.5% | $200M— | $0-100% | ||
| $9.84M+18.5% | $8.31M-42.3% | $14.39M-61.8% | $37.71M-1.0% | ||
| $1.99B+2.5% | $1.94B+1.5% | $1.91B+3.0% | $1.85B-23.3% | ||
| $115.85M-13.6% | $134.09M-11.7% | $151.95M-7.1% | $163.63M+18.9% | ||
| $131.72M-8.2% | $143.46M-6.8% | $153.99M-1.9% | $156.92M-10.1% | ||
| $24.37M+53.9% | $15.83M+701% | $1.98M-57.4% | $4.64M-12.3% | ||
| $2.27B+1.0% | $2.24B+0.6% | $2.23B-0.6% | $2.24B-18.5% | ||
| $11.14M-24.3% | $14.71M-61.4% | $38.15M+39.1% | $27.43M+85.1% | ||
| $13.11M+25.9% | $10.42M+103% | $5.14M+25,605% | $20K-88.3% | ||
| $15.77M+310% | $3.85M-6.3% | $4.11M— | $0-100% | ||
| $18.58M+7.5% | $17.29M+10.6% | $15.63M-1.4% | $15.84M+30.3% | ||
| $1.11M+147% | $451K+3.0% | $438K+224% | $135K-81.4% | ||
| $149.12M+69.9% | $87.78M-19.3% | $108.79M-10.2% | $121.11M+1.0% | ||
| $0— | —— | —— | —— | ||
| $188.17M-8.8% | $206.41M-7.4% | $223.01M-2.3% | $228.18M+7.2% | ||
| $6.14M+78.3% | $3.44M+259% | $958K-84.0% | $5.97M-18.7% | ||
| $343.43M+10.8% | $309.95M-10.6% | $346.77M-5.7% | $367.58M+4.3% | ||
| $3.09M+14.4% | $2.7M+8.0% | $2.5M+2.3% | $2.44M+2.1% | ||
| $3.86B+17.2% | $3.29B+14.4% | $2.88B+5.2% | $2.73B+5.3% | ||
| -$1.95B-42.6% | -$1.37B-36.6% | -$999.7M-18.2% | -$846.09M-332% | ||
| $4.82M+162% | $1.84M-3.8% | $1.91M+112% | -$15.65M-209% | ||
| $60K-3.2% | $62K0.0% | $62K-1.6% | $63K0.0% | ||
| $1.92B-0.5% | $1.93B+2.6% | $1.88B+0.4% | $1.88B-21.8% | ||
| $2.27B+1.0% | $2.24B+0.6% | $2.23B-0.6% | $2.24B-18.5% | ||
| $1.63B+1.4% | $1.61B+23.1% | $1.3B-18.7% | $1.6B+10.1% | ||
| $24.37M+53.9% | $15.83M+701% | $1.98M-57.4% | $4.64M-12.3% | ||
| $131.72M-8.2% | $143.46M-6.8% | $153.99M-1.9% | $156.92M-10.1% | ||
| $131.72M-8.2% | $143.46M-6.8% | $153.99M-1.9% | $156.92M-10.1% | ||
| $24.37M+53.9% | $15.83M+701% | $1.98M-57.4% | $4.64M-12.3% | ||
| $131.72M-8.2% | $143.46M-6.8% | $153.99M-1.9% | $156.92M-10.1% | ||
| $24.37M+53.9% | $15.83M+701% | $1.98M-57.4% | $4.64M-12.3% | ||
| $89.41M+118% | $41.07M-9.4% | $45.34M-41.6% | $77.68M-14.6% | ||
| $89.41M+118% | $41.07M-9.4% | $45.34M-41.6% | $77.68M-14.6% | ||
| $13.11M+25.9% | $10.42M+103% | $5.14M+25,605% | $20K-88.3% | ||
| $206.75M-7.6% | $223.69M-6.3% | $238.63M-2.2% | $244.02M+8.4% | ||
| $3.86B+17.2% | $3.29B+14.4% | $2.88B+5.2% | $2.73B+5.3% | ||
| $3.09M+14.4% | $2.7M+8.0% | $2.5M+2.3% | $2.44M+2.1% | ||
| $60K-3.2% | $62K0.0% | $62K-1.6% | $63K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CRISPR Therapeutics's total assets?
- CRISPR Therapeutics (CRSP) holds $2.7B in total assets, up 25.8% year over year.
- How much debt does CRISPR Therapeutics have?
- CRISPR Therapeutics carries $787.6M in total debt against $1.8B of shareholders' equity, a debt-to-equity ratio of 0.43.
- How much cash does CRISPR Therapeutics have?
- CRISPR Therapeutics holds $423.3M in cash and equivalents.
- Can CRISPR Therapeutics cover its short-term obligations?
- Its current ratio is 17.96 — current assets exceed current liabilities.
- Where does CRISPR Therapeutics's balance sheet data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
